INOVIO Pharmaceuticals Files 2025 Proxy Statement
Ticker: INO · Form: DEF 14A · Filed: Apr 7, 2025 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | DEF 14A |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: INO
TL;DR
INOVIO proxy statement out, details exec pay for Shea & Kim. #investing #governance
AI Summary
INOVIO Pharmaceuticals, Inc. filed its DEF 14A on April 7, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including compensation for Jacqueline E. Shea, Ph.D., a member of the board, for the fiscal years 2022, 2023, and 2024. It also references compensation for J. Joseph Kim, Ph.D., a member, for the fiscal year 2022.
Why It Matters
This filing provides transparency into executive and board compensation, which can influence investor decisions and perceptions of company governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal underlying company performance or strategic direction.
Key Numbers
- 2024 — Fiscal Year (Compensation details for this year are included.)
- 2023 — Fiscal Year (Compensation details for this year are included.)
- 2022 — Fiscal Year (Compensation details for this year are included.)
Key Players & Entities
- INOVIO PHARMACEUTICALS, INC. (company) — Filer
- Jacqueline E. Shea, Ph.D. (person) — Board Member
- J. Joseph Kim, Ph.D. (person) — Board Member
- 2024-12-31 (date) — Fiscal Year End
- 20250407 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing for INOVIO Pharmaceuticals, Inc.?
The primary purpose is to provide information to shareholders regarding the company's annual meeting, including details on executive compensation, board of directors, and other corporate governance matters.
Who are the key individuals whose compensation is detailed in this filing?
The filing details compensation for board members such as Jacqueline E. Shea, Ph.D., and J. Joseph Kim, Ph.D., for various fiscal years.
For which fiscal years are compensation details provided for Jacqueline E. Shea, Ph.D.?
Compensation details for Jacqueline E. Shea, Ph.D. are provided for the fiscal years 2022, 2023, and 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 7, 2025.
What is the reported fiscal year end for INOVIO Pharmaceuticals, Inc.?
The reported fiscal year end for INOVIO Pharmaceuticals, Inc. is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 7, 2025 by Jacqueline E. Shea, Ph.D. regarding INOVIO PHARMACEUTICALS, INC. (INO).